Pfizer Abandons Twice-Daily Weight Loss Pill Following Dismal Study Findings

Pfizer said it would not move its twice-daily oral weight-loss drug danuglipron into late-stage research after patients experienced nausea and vomiting.

Related Keywords

,Albert Bourla ,Novo Nordisk Wegovy ,Eli Lilly ,Pfizer ,Novo Nordisk ,Everything You Need ,Getty Images ,Active Ingredient ,Weight Loss Treatment ,Bandons Twice ,Daily ,Eight ,Boss ,Hill ,Following ,Dismal ,Study ,Findings ,